Trial · NCT00428948
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36 | Tolvaptan | 2.777 | Standard Deviation 5.659 | Percentage change per year | |
| Percentage Change Per Year in Total Kidney Volume From Baseline to Month 36 | Placebo | 5.608 | Standard Deviation 5.330 | Percentage change per year | |
| Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36 | Tolvaptan | 43.94 | Events/100 follow-up years | ||
| Number of ADPKD Clinical Progression Events Per 100 Follow-up Years From Baseline to Month 36 | Placebo | 50.04 | Events/100 follow-up years | ||
| Change in Renal Function Per Year From Week 3 to Month 36 | Tolvaptan | -2.555 | Standard Deviation 9.767 | (mg/mL)^-1 per year | |
| Change in Renal Function Per Year From Week 3 to Month 36 | Placebo | -3.682 | Standard Deviation 6.361 | (mg/mL)^-1 per year | |
| Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36 | Tolvaptan | 2.561 | Standard Deviation 9.798 | mmHg | |
| Change in Mean Arterial Blood Pressure Per Year in Non-hypertensive Participants From Baseline to Month 36 | Placebo | 2.592 | Standard Deviation 7.095 | mmHg | |
| Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36 | Tolvaptan | -0.00 | Standard Deviation 1.29 | units on a scale | |
| Area Under the Concentration-time Curve of Change in Renal Pain From Baseline to Month 36 | Placebo | 0.08 | Standard Deviation 1.43 | units on a scale | |
| Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36 | Tolvaptan | 31.80 | Events/100 follow-up years | ||
| Number of Hypertensive Events Per 100 Follow-up Years in Non-hypertensive Participants From Baseline to Month 36 | Placebo | 29.60 | Events/100 follow-up years | ||
| Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36 | Tolvaptan | 6.24 | Percentage of participants | ||
| Percentage of Participants With a Clinically Sustained Decrease of Blood Pressure Leading to a Sustained Reduction in Antihypertensive Therapy From Baseline to Month 36 | Placebo | 5.62 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00428948/results